Humacyte, Inc. (NASDAQ:HUMA) Receives $8.29 Consensus PT from Analysts

by · The Markets Daily

Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) have received an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $8.2857.

A number of equities analysts have recently weighed in on HUMA shares. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a research note on Monday, December 1st. UBS Group reissued a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Monday, December 22nd. Finally, Benchmark lowered their target price on shares of Humacyte from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, November 13th.

Check Out Our Latest Stock Report on Humacyte

Humacyte Stock Up 1.5%

Shares of HUMA stock opened at $0.98 on Monday. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. Humacyte has a one year low of $0.91 and a one year high of $5.33. The company’s fifty day moving average price is $1.26 and its 200-day moving average price is $1.70. The company has a market capitalization of $182.59 million, a price-to-earnings ratio of -4.24 and a beta of 1.93.

Humacyte (NASDAQ:HUMA – Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.92 million. Sell-side analysts expect that Humacyte will post -1.27 EPS for the current fiscal year.

Institutional Trading of Humacyte

Several hedge funds have recently bought and sold shares of HUMA. RA Capital Management L.P. purchased a new position in shares of Humacyte during the first quarter valued at about $5,648,000. Marshall Wace LLP boosted its stake in Humacyte by 5,308.2% during the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after buying an additional 2,590,394 shares during the last quarter. CenterBook Partners LP grew its holdings in Humacyte by 141.1% during the 2nd quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock valued at $7,169,000 after buying an additional 2,007,743 shares in the last quarter. Woodline Partners LP increased its stake in Humacyte by 38.7% in the 1st quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock worth $6,735,000 after acquiring an additional 1,101,198 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Humacyte by 33.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock worth $6,163,000 after acquiring an additional 738,142 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

(Get Free Report)

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

Further Reading